Pluri (FRA:4DX) Tariff Resilience Score: 6/10 (As of Jul. 04, 2026)


FRA:4DX Pluri Inc FRA:4DX
25 GF Score
Price €5.60
GF Value €17.25
! 6 Warning Signs
View Full Analysis

What is Pluri Tariff Resilience Score?

Pluri FRA:4DX 25 Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus rates FRA:4DX with a GF Score™ of 25/100 and a GF Value™ of €17.25. The stock has 6 warning signs investors should review. Among 1,373 Biotechnology companies, Pluri ranks better than 75.97% on this metric.

Pluri has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Pluri has Pluri Inc's biotech focus involves international supply chains, but the industry benefits from some tariff exemptions. The company has moderate exposure, with potential to shift suppliers. Historical impacts have been limited, with some pricing flexibility.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Pluri might have Average Resilient.

Pluri  (FRA:4DX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Pluri Tariff Resilience Score Related Terms

FRA:4DX vs MRKR, VYNE, LGVN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Pluri's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pluri Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Pluri's Tariff Resilience Score falls into.


FRA:4DX
25GF Score
Pluri Inc FRA:4DX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Pluri (FRA:4DX) has a Tariff Resilience Score of 6 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Pluri ranks #330 out of 1373 companies in the Biotechnology industry, placing it in the top 24%.
Is Pluri's Tariff Resilience Score too high?
Pluri's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Pluri's value of 6 is 50% above this industry median. Based on the distribution chart, Pluri ranks #330 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pluri has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Pluri's Tariff Resilience Score compare to MRKR and VYNE?
According to the Biotechnology industry distribution chart, Pluri ranks #330 out of 1373 companies for Tariff Resilience Score. This places Pluri in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Pluri's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pluri's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pluri's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Pluri (FRA:4DX) has a current Tariff Resilience Score of 6. The stock's GF Value™ is €17.25, compared to a current price of €5.60 — trading 67.5% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Pluri (FRA:4DX), the current Tariff Resilience Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pluri (FRA:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of €5.60 is trading 67.5% below its estimated GF Value™ of €17.25.

Key valuation signals for FRA:4DX:

  • Tariff Resilience Score: 6
  • GF Value™: €17.25 vs. price of €5.60 (67.5% below fair value)
  • GF Score™: 25/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#330 of 1373)

No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pluri Business Description

Other Exchanges PLUR:USAPLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for FRA:4DX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.60
Price
€17.25
GF Value